MedPacto Inc (235980) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of MedPacto Inc KRW 1,234, price KRW 2,805, upside -56.0%, quality 47 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch MedPacto Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
MedPacto, Inc. engages in the development and sale of marker-based new drugs in South Korea. MedPacto, Inc. was established in 2013 and is based in Seoul, South Korea.
Stock analysis
MedPacto Inc (235980) currently trades at 2,805 KRW, while our model-based Fair Value estimate is 1,234 KRW, implying the stock looks roughly 127.4% overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.
Scenario range: 814.25 KRW (bear) to 1,542 KRW (bull), the price of 2,805 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 47/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue growth is weak, negative or inconsistent.
MedPacto Inc reported revenue of 3.9B KRW in FY2025 versus 0 KRW in FY2021. Reported net income was −12.8B KRW in FY2025.
Key figures
Market cap 96.1B KRW (≈ $70.7M) · P/S ratio 18.7 · Net margin −276% · Return on equity −27.2% · Return on assets (EBIT) −33.1% · Operating margin −316% · Revenue (TTM) 4.8B KRW · Revenue growth (YoY) +206%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (medium confidence).
What moves the price
The share trades about 65% below its 52-week high and 25% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −5% fair-value upside, at −56%, 235980 screens richer than that median.
Fair Value models
Bear 814.25 KRWFair Value 1,234 KRWBull 1,542 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 654 stocks
Beats the industry median on 4/6 measures
Overall it ranks above its industry peers.
Valuation
Quality Score48 · Above median
Fair Value upside−56% · Below median
Profitability
Return on assets−18% · Below median
Growth and dividend
Revenue growth206% · Top 25%
Balance sheet
Debt / equity0.05× · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/S (TTM)0.02× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)97· sector 97
DIVIDEND (yield)0· sector 23
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "MedPacto Inc Fair Value". https://www.fairvalue-calculator.com/stock/235980
Frequently asked questions
Is MedPacto Inc (235980) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,234 KRW versus a price of 2,805 KRW, about −56% upside (overvalued).
What is the fair value of 235980?
Our model-based fair value for MedPacto Inc is 1,234 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 2,805 KRW.
What is the quality score of 235980?
MedPacto Inc has a Quality Score of 47/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for MedPacto Inc (235980)?
Our model-based price target is the fair value of 1,234 KRW (as of Sep 24, 2026) from 1 valuation models. Cautious scenario 814.25 KRW, optimistic scenario 1,542 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the MedPacto Inc stock forecast for 2026?
Our models put fair value at 1,234 KRW, about −56% upside versus a price of 2,805 KRW (overvalued). Cautious scenario 814.25 KRW, optimistic scenario 1,542 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of MedPacto Inc (235980)?
MedPacto Inc reported trailing-twelve-month revenue of about 4.8B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of MedPacto Inc (235980)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For MedPacto Inc it is 1,234 KRW per share (as of Sep 24, 2026), against a price of 2,805 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is MedPacto Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 235980 trades above its calculated fair value: price 2,805 KRW, fair value 1,234 KRW, a gap of about −56% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 235980?
No. The price is what the market pays today (2,805 KRW); the fair value is what the company's own numbers justify (1,234 KRW). For MedPacto Inc the two are 1,571 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is MedPacto Inc worth?
The market values MedPacto Inc at about 96.1B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 2,805 KRW; our models calculate a fair value of 1,234 KRW per share.
What do the bullish and bearish scenarios say about 235980?
Our models span a range for MedPacto Inc: cautious scenario 814.25 KRW, base 1,234 KRW, optimistic 1,542 KRW per share (as of Sep 24, 2026, price 2,805 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of MedPacto Inc (235980)?
Balance-sheet figures for MedPacto Inc (as of Sep 24, 2026): return on equity −27.2%, debt of 0.05 per unit of equity. They feed the Quality Score of 47/100, which measures business quality independently of the share price.
How far is 235980 from its 52-week high?
MedPacto Inc trades at 2,805 KRW, about 65% below its 52-week high of 8,050 KRW and 25% above the low of 2,240 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,234 KRW is for.
Which stocks are comparable to MedPacto Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, Samsung Biologics Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is MedPacto Inc stock attractive at the current price?
The data as of Sep 24, 2026: price 2,805 KRW, calculated fair value 1,234 KRW (−56%), Quality Score 47/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 235980 calculated?
We run MedPacto Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,234 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. MedPacto Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of MedPacto Inc (235980)?
The closing price on Sep 23, 2026 was 2,805 KRW. Our model-based fair value is 1,234 KRW, about −56% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with MedPacto Inc right now?
The price sits above even our optimistic bull case (1,542 KRW). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (814.25 KRW to 1,542 KRW) leaves room in how you read the outcome.
Key figures of MedPacto Inc
How large is the market capitalisation of MedPacto Inc (235980)?
The market capitalisation of MedPacto Inc is 96.1B KRW (≈ $70.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of MedPacto Inc (235980)?
The price-to-sales ratio of MedPacto Inc is 18.7 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of MedPacto Inc (235980)?
The net margin of MedPacto Inc is −276% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of MedPacto Inc (235980)?
The return on equity (ROE) of MedPacto Inc is −27.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of MedPacto Inc (235980)?
On an EBIT basis the return on assets of MedPacto Inc is −33.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of MedPacto Inc (235980)?
The operating margin of MedPacto Inc is −316% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at MedPacto Inc (235980)?
Revenue at MedPacto Inc is growing +206% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does MedPacto Inc (235980) generate?
The free cash flow of MedPacto Inc is −13.6B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does MedPacto Inc (235980) carry?
The net debt of MedPacto Inc is 59.9B KRW (fiscal year 2022). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch MedPacto Inc in the live analysis
One click puts MedPacto Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
